Chiesi Completes Acquisition of KalVista, Expanding Rare Disease Portfolio with EKTERLY

Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, strengthening its position in the rare disease market through the addition... Read More

The post Chiesi Completes Acquisition of KalVista, Expanding Rare Disease Portfolio with EKTERLY appeared first on citybiz.